Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's ...

California-based medical device company Axonics has won a patent infringement trial against Medtronic, according to a Sept. 19 report from Global Data. Medtronic alleged that the company copied three ...

From new leadership and expansions, here are five key updates from spine and orthopedic devicemakers since Sept. 11.

Medtronic secured approval from the US Food and Drug Administration (FDA) for its closed-loop spinal cord stimulation (SCS) ...

For instance, in 2016, Medtronic created the first hybrid closed-loop insulin delivery system; in 2017, it made the world's smallest spinal cord stimulator implant. Is Medtronic the Largest ...

Axonics Inc. (NASDAQ:AXNX) rose 1.5% in after hours trading after a jury voted in is favor in a patent dispute with Medtronic ...

Medtronic has recalled McGrath MAC Video Laryngoscopes because of an increased risk of the battery overheating, which can result in explosion. The FDA has identified the type of recall as serious ...

Medtronic faced challenges ... insulin pumps, neuromodulators, spinal products, acute care & monitoring, etc. This scale and leadership lead to switching costs. Competitors must demonstrate ...

catalog albums the week's most popular albums across all genres at least 18 months old and that have fallen below no. 100 on the billboard 200, based on multimetric consumption, blending ...

Medtronic delivered a strong first-quarter earnings report. The company benefits from continued market adoption of several new product launches over the past year. The stock looks attractive ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Medical device giant Medtronic (NYSE: MDT) has been somewhat of a stock market laggard over the past five years, partly due to pandemic-related disruptions. Even beyond this global issue ...